Dexcom Inc (DXCM): who owns it and who trades it
As of Nov 16, 2026, DXCM insiders reported 29 open-market sales worth $12.5M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Kevin R Sayer (Chair), with $8.3M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Dexcom
From the latest filingsOverall: about as much buying as selling. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns DXCM
966 funds and institutions reported DXCM shares worth $26.2B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 9.9%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 38.24M | 9.91% | $2.6B | -2% |
| Vanguard Capital Management LLC | 25.21M | 6.53% | $1.7B | +1% |
| Vanguard Portfolio Management LLC | 19.66M | 5.09% | $1.3B | +2% |
| State Street Corp | 18.38M | 4.76% | $1.2B | +2% |
| Invesco Ltd. | 15.29M | 3.96% | $1B | +173% |
| Baillie Gifford & Co | 14.80M | 3.84% | $997M | -5% |
| Geode Capital Management, LLC | 12.43M | 3.22% | $834M | +1% |
| Alliancebernstein L.P. | 11.69M | 3.03% | $734M | -10% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 11.26M | 2.92% | $758M | +16% |
| Wellington Management Group LLP | 8.53M | 2.21% | $574M | -9% |
| Arrowstreet Capital, Limited Partnership | 6.87M | 1.78% | $463M | +170% |
| Norges Bank | 6.87M | 1.78% | $463M | – |
| UBS Group AG | 6.07M | 1.57% | $409M | +39% |
| Amundi | 5.60M | 1.45% | $377M | -12% |
| Morgan Stanley | 5.16M | 1.34% | $347M | +2% |
| Ameriprise Financial Inc | 4.82M | 1.25% | $325M | +14% |
| Castle Hook Partners LP | 3.87M | 1.00% | $261M | +383% |
| Goldman Sachs Group Inc | 3.76M | 0.97% | $253M | +23% |
| Franklin Resources Inc | 3.60M | 0.93% | $242M | +38% |
| Massachusetts Financial Services Co | 3.56M | 0.92% | $241M | +84% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, DXCM insiders reported $0 of open-market purchases and $12.5M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 27, 2026 | Sadie Stern | Vice president | Sale plan | 2,565 | $78.62 | $202K | Form 4 |
| Oct 15, 2026 | Michael Jon Brown | Vice president | Sale plan | 1,700 | $85.48 | $145K | Form 4 |
| Sep 28, 2026 | Sadie Stern | Vice president | Sale plan | 2,565 | $86.15 | $221K | Form 4 |
| Sep 15, 2026 | Nicholas Augustinos | Director | Sale plan | 6,539 | $84.04 | $550K | Form 4 |
| Sep 15, 2026 | Michael Jon Brown | Vice president | Sale plan | 1,700 | $84.04 | $143K | Form 4 |
| Sep 14, 2026 | Nicholas Augustinos | Director | Sale plan | 1,550 | $84.02 | $130K | Form 4 |
| Sep 10, 2026 | Jereme M Sylvain | Vice president | Sale plan | 3,638 | $83.27 | $303K | Form 4 |
| Aug 27, 2026 | Sadie Stern | Vice president | Sale plan | 2,565 | $88.37 | $227K | Form 4 |
| Aug 20, 2026 | Kevin R Sayer | Chair | Sale plan | 19,308 | $89.71 | $1.7M | Form 4 |
| Aug 20, 2026 | Kevin R Sayer | Chair | Sale plan | 7,351 | $90.78 | $667K | Form 4 |
| Aug 20, 2026 | Kevin R Sayer | Chair | Sale plan | 97 | $91.41 | $8.9K | Form 4 |
| Aug 14, 2026 | Michael Jon Brown | Vice president | Sale plan | 1,700 | $91.93 | $156K | Form 4 |
| Aug 12, 2026 | Bridgette P Heller | Director | Sale plan | 1,012 | $88.29 | $89.3K | Form 4 |
| Aug 3, 2026 | Mark G Foletta | Director | Sale plan | 2,000 | $85.32 | $171K | Form 4 |
| Jul 31, 2026 | Mark G Foletta | Director | Sale plan | 2,000 | $80.00 | $160K | Form 4 |
| Jul 20, 2026 | Kevin R Sayer | Chair | Sale plan | 26,756 | $76.32 | $2M | Form 4 |
| Jul 15, 2026 | Michael Jon Brown | Vice president | Sale plan | 1,700 | $74.42 | $127K | Form 4 |
| Jul 6, 2026 | Kevin R Sayer | Chair | Sale plan | 26,756 | $72.00 | $1.9M | Form 4 |
| Jun 15, 2026 | Michael Jon Brown | Vice president | Sale plan | 1,700 | $75.55 | $128K | Form 4 |
| Jun 15, 2026 | Mark G Foletta | Director | Sale plan | 199 | $74.82 | $14.9K | Form 4 |
| Jun 15, 2026 | Mark G Foletta | Director | Sale plan | 3,801 | $74.10 | $282K | Form 4 |
| Jun 4, 2026 | Jon Coleman | Vice president | Sale plan | 4,911 | $74.13 | $364K | Form 4 |
| Jun 3, 2026 | Jon Coleman | Vice president | Sale plan | 4,912 | $73.00 | $359K | Form 4 |
| May 21, 2026 | Kevin R Sayer | Chair | Sale plan | 26,759 | $72.00 | $1.9M | Form 4 |
| May 15, 2026 | Michael Jon Brown | Vice president | Sale plan | 1,700 | $59.91 | $102K | Form 4 |
| May 12, 2026 | Bridgette P Heller | Director | Sale plan | 1,012 | $60.01 | $60.7K | Form 4 |
| Apr 15, 2026 | Michael Jon Brown | Vice president | Sale plan | 1,700 | $63.04 | $107K | Form 4 |
| Mar 16, 2026 | Michael Jon Brown | Vice president | Sale plan | 1,700 | $64.85 | $110K | Form 4 |
| Feb 12, 2026 | Bridgette P Heller | Director | Sale plan | 1,012 | $68.01 | $68.8K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Kevin R Sayer | Executive Chair, Director | – | $8.3M | Aug 20, 2026 |
| Michael Jon Brown | EVP, Chief Legal Officer | – | $1M | Oct 15, 2026 |
| Jon Coleman | EVP, Chief Commercial Officer | – | $723K | Jun 4, 2026 |
| Nicholas Augustinos | Director | – | $680K | Sep 15, 2026 |
| Sadie Stern | EVP Chief People & Culture Off | – | $649K | Oct 27, 2026 |
| Mark G Foletta | Director | – | $627K | Aug 3, 2026 |
| Jereme M Sylvain | EVP, Chief Financal Officer | – | $303K | Sep 10, 2026 |
| Bridgette P Heller | Director | – | $219K | Aug 12, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
DXCM short interest
Low short interest. 4.3% of DXCM shares are sold short: about 1 share in 23. Over the last 12 reports the number of shares short went down 9%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 15.93M DXCM shares were sold short, 4.3% of the shares outstanding, up 1.5% from the report before. At the average daily volume of 5.68M shares, buying them all back would take about 2.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 15.93M | 4.27% | +2% | 5.68M | 2.8 |
| Oct 15, 2026 | 15.69M | 4.16% | +12% | 3.30M | 4.8 |
| Sep 30, 2026 | 14.02M | 3.71% | -19% | 4.44M | 3.2 |
| Sep 15, 2026 | 17.26M | 4.57% | -2% | 3.46M | 5.0 |
| Aug 31, 2026 | 17.63M | 4.67% | +7% | 4.09M | 4.3 |
| Aug 14, 2026 | 16.53M | 4.38% | -6% | 5.62M | 2.9 |
| Jul 31, 2026 | 17.55M | 4.65% | -6% | 5.09M | 3.5 |
| Jul 15, 2026 | 18.65M | 4.83% | +3% | 4.27M | 4.4 |
| Jun 30, 2026 | 18.11M | 4.69% | +6% | 5.03M | 3.6 |
| Jun 15, 2026 | 17.02M | 4.41% | -2% | 5.38M | 3.2 |
| May 29, 2026 | 17.39M | 4.51% | -1% | 8.45M | 2.1 |
| May 15, 2026 | 17.56M | 4.55% | -4% | 6.31M | 2.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded DXCM
Since Nov 17, 2024, 5 members of Congress reported 4 purchases and 6 sales of DXCM. The latest was a sale by Tina Smith on May 7, 2026, reported May 10, 2026.
Purchases 4Sales 6
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| May 7, 2026 | Tina Smith (D-MN) | Sale | $100K–$250K | Spouse | May 10, 2026 | Report |
| Apr 29, 2026 | Tina Smith (D-MN) | Partial sale | $100K–$250K | Spouse | May 10, 2026 | Report |
| Jan 26, 2026 | John Boozman (R-AR) | Purchase | $1K–$15K | Joint | Feb 15, 2026 | Report |
| May 15, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Purchase | $1K–$15K | Self | Jun 9, 2025 | Report |
| May 12, 2025 | Jefferson Shreve (R-IN) | Sale | $15K–$50K | Self | Jun 22, 2025 | Report |
| May 8, 2025 | Jefferson Shreve (R-IN) | Purchase | $15K–$50K | Self | Jun 22, 2025 | Report |
| Apr 8, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Sale | $1K–$15K | Self | Apr 28, 2025 | Report |
| Apr 7, 2025 | Jefferson Shreve (R-IN) | Sale | $15K–$50K | Self | May 8, 2025 | Report |
| Feb 25, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Purchase | $1K–$15K | Self | Mar 27, 2025 | Report |
| Dec 31, 2024 | Kevin Hern (R-OK) | Sale | $50K–$100K | Joint | Jan 15, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Dexcom company events
Dexcom filed 12 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership). The latest was on Oct 29, 2026.
- Oct 29, 2026AnnouncementDexcom announced that its Board of Directors authorized and approved a share repurchase program of up to $1.0 billion of Dexcom’s outstanding common stock, par value $0.001 per share, with a repurchase period ending no later than December 31, 2027. Filing
- Sep 14, 2026LeadershipThe Board of Directors of DexCom, Inc. appointed Jereme Sylvain, the Company’s EVP, Chief Financial Officer, to the role of EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026. Filing
- Sep 10, 2026LeadershipThe Board of Directors of DexCom, Inc., pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to thirteen directors and appointed Glenn S. Boehnlein as a director, effective immediately. Filing
- Jul 30, 2026ResultsReleased financial results. Filing
- May 28, 2026VoteReported shareholder vote results. Filing
- May 15, 2026AnnouncementDexcom announced that its Board of Directors authorized and approved a share repurchase program of up to $1.0 billion of Dexcom’s outstanding common stock, par value $0.001 per share, with a repurchase period ending no later than June 30, 2027. Filing
- Apr 30, 2026ResultsReleased financial results. Filing
- Mar 2, 2026LeadershipAs previously reported on the Current Report on Form 8-K filed on July 30, 2025, Kevin R. Sayer notified the Board of Directors of DexCom, Inc. of his intent to retire from his role as Chief Executive Officer effective January 1, 2026. Filing
- Feb 26, 2026LeadershipThe Board of Directors of DexCom, Inc., pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to twelve directors and appointed Albert F. Osterloh, IV as a director effective immediately. Filing
- Feb 12, 2026ResultsReleased financial results. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Dec 22, 2025LeadershipAs previously reported on the Current Report on Form 8-K filed on July 30, 2025, the Board of Directors of DexCom, Inc. appointed Jacob S. Leach, President and Chief Operating Officer, as the President and Chief Executive Officer and as a director of the Company, effective January 1, 2026… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Dexcom financials
Famous investors that hold DXCM
5 of the 50 well-known investors we track reported holding DXCM in their latest 13F filing. The largest position is Ken Griffin's, worth $357M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 4.14M | $357M | 0.2% | +241% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 2.35M | $202M | 0.3% | +44% |
| Israel Englander · Millennium Management | Q3 2026 | 992,370 | $85.6M | 0.1% | +151% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 341,488 | $29.5M | 0.1% | -15% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 58,484 | $5M | 0.0% | -4% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named DXCM in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 5.0% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 5.0% |
Questions about Dexcom Inc (DXCM) stock
Who owns the most DXCM stock?
The largest reported owner of Dexcom Inc (DXCM) is BlackRock, Inc., with 9.9% of the company. In total, 966 funds and institutions reported holding DXCM at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are DXCM insiders buying or selling?
In the last 12 months, DXCM insiders reported no open-market purchases and 29 sales worth $12.5M. The latest trade was on Oct 27, 2026. See every trade.
What is the short interest in DXCM?
As of Oct 30, 2026, 15.93M DXCM shares were sold short, 4.3% of the shares outstanding, up 1.5% from the report before. At the average daily volume of 5.68M shares, buying them all back would take about 2.8 trading days (days to cover). See the history.
Have members of Congress traded DXCM?
Yes. 5 members of Congress reported 4 purchases and 6 sales of DXCM since Nov 17, 2024. The latest was reported on May 10, 2026. See the trades.
Which famous investors hold DXCM?
5 of the 50 well-known investors we track reported DXCM in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $357M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.